Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Kathy L Mcgraw, PhD, Johnny Nguyen, Najla Alali, MS, Jinming Song, MD PhD, David Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Daihui Qin, P.K. Epling-Burnette, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Alan F List, MD, Ling Zhang, MD

Blood (2016) 128 (22): 4305.

https://doi.org/10.1182/blood.V128.22.4305.4305

Published: 2016

Journal Articles

Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML)

Maria E. Balasis, Jane Merelvede, Sateesh Kunigal, Xiaoyi Ren, Yan Ma, Qing Zhang, PhD, Jeff Painter, Nathalie M. Droin, PhD, Joseph Johnson, Sean Yoder, M.S, Rami S. Komrokji, MD, Ling Zhang, MD, Sheng Wei, MD, Torsten Haferlach, Robert MacLeod, PhD, Alan F. List, MD, Eric Solary, MD Prof, P.K. Epling-Burnette, PhD, Eric Padron, MD

Blood (2015) 126 (23): 1641.

https://doi.org/10.1182/blood.V126.23.1641.1641

Published: 2015

Journal Articles

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Blood (2012) 120 (21): 2823.

https://doi.org/10.1182/blood.V120.21.2823.2823

Published: 2012

Journal Articles

Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC)

Sheng Wei, MD, Xianghong Chen, Junmin Zhou, Ph.D, Ling Zhang, MD, Nicole R. Fortenbery, Sarah S Rasche, Ph.D, Kathy McGraw, Erika A. Eksioglu, Ph.D, P.K. Epling-Burnette, PhD, Julie Y. Djeu, Ph.D, Dmitry I. Gabrilovich, Ph.D, Alan F. List, MD

Blood (2011) 118 (21): 788.

https://doi.org/10.1182/blood.V118.21.788.788

Published: 2011

Journal Articles

Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes.

Amber Schmidt, Rami S. Komrokji, MD, Jeffrey S. Painter, B.S., Dana E Rollison, PhD, Ling Zhang, MD, Lynn C. Moscinski, MD, Alan F List, MD, P.K. Epling-Burnette, PhD

Blood (2009) 114 (22): 1572.

https://doi.org/10.1182/blood.V114.22.1572.1572

Published: 2009

Journal Articles

Functional T Cell Array Reveals Pre-Treatment Expanded Terminal Effector Memory Response Is Associated with Lenalidomide Failure in Non-Del(5q) Myelodysplastic Syndrome.

P.K. Epling-Burnette, PhD, JianXiang Zou, MD, Jeffrey S. Painter, B.S., Dung-Tsa Chen, Jimmy Fulp, Rami S. Komrokji, MD, Sheng Wei, MD, Alan F List, MD

Blood (2009) 114 (22): 1759.

https://doi.org/10.1182/blood.V114.22.1759.1759

Published: 2009

Journal Articles

Pathogenetic Role of Impaired Telomere Repair in Myelodysplastic Syndrome.

P.K. Epling-Burnette, PhD, Alan F List, MD, Justine Clark, MS, Ji-Hyun Lee, Kristen A. Jonathan, William Fulp, Xiaohong Li, Weipeng Zheng, Jeffrey S. Painter, B.S., JianXiang Zou, MD, Rami S. Komrokji, MD, Sheng Wei, MD, Jong Park, Amber Schmidt, Undergraduate, student, Chiharu Sugimori, MD, Ashley Cole, Dana E Rollison, PhD

Blood (2009) 114 (22): 2777.

https://doi.org/10.1182/blood.V114.22.2777.2777

Published: 2009

Journal Articles

Co-Existance of JAK V617F and PIG-A mutations in Primary Budd-Chiari Syndrome.

Chiharu Sugimori, MD, Kenneth H Shain, MD, PhD, Gisela Caceres, PhD, Lubomir Sokol, MD, PhD, David Araten, MD, Jaroslaw P. Maciejewski, MD, PhD, JianXiang Zou, MD, P.K. Epling-Burnette, PhD, Alan F List, MD

Blood (2009) 114 (22): 3193.

https://doi.org/10.1182/blood.V114.22.3193.3193

Published: 2009

Journal Articles

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Sheng Wei, MD, Xianghong Chen, PhD, Kathy Rocha, Dahui Qi, MD, Jianguo Tao, MD, PhD, Nicole Gjertsen, Junmin Zhou, Ph.D, Jinhong Liu, M.D., Dmitry Gabrilovich, MD, PhD, P.K. Epling-Burnette, PhD, Julie Y Djeu, PhD, Alan F. List, MD

Blood (2009) 114 (22): 597.

https://doi.org/10.1182/blood.V114.22.597.597

Published: 2009

Journal Articles

Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy.

John J. Powers, B.S., Jason A Dubovsky, B.S., Ling Zhang, MD, Lynn C. Moscinski, MD, P.K. Epling-Burnette, PhD, Eduardo M. Sotomayor, MD, Javier Pinilla, MD, PhD

Blood (2009) 114 (22): 2204.

https://doi.org/10.1182/blood.V114.22.2204.2204

Published: 2009

Journal Articles

Altered Naive and Memory T Cell Homeostasis and Immunosenescence Characterize Younger Patients with Immunosuppressive-Responsive Myelodysplastic Syndrome

JianXiang Zou, MD, Dana E Rollison, PhD, David Boulware, MS, Elaine M. Sloand, MD, Loretta Pfannes, BS, Fanqi Bai, MD, Jeffrey S. Painter, BS, Sheng Wei, MD, Denise Cosgrove, RN, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2008) 112 (11): 3647.

https://doi.org/10.1182/blood.V112.11.3647.3647

Published: 2008

Journal Articles

Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS)

Chiharu Sugimori, MD, JianXiang Zou, MD, Christine O’Keefe, PhD, Michael Clemente, MS, Tie-Ying Wei, BS, Jaroslaw Maciejewski, Thomas P. Loughran, Jr., MD, Ron Paquette, MD, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2008) 112 (11): 3654.

https://doi.org/10.1182/blood.V112.11.3654.3654

Published: 2008

Journal Articles

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

P.K. Epling-Burnette, PhD, Jeffrey S. Painter, BS, H.-S. Lee, PhD, Jong Park, Michael Clemente, MS, Christine O’Keefe, MD, Tie-Ying Wei, BS, Sheng Wei, MD, Jaroslaw Maciejewski, Thomas P. Loughran, Jr., MD, Ron Paquette, MD, Alan F. List, MD, Julie Y Djeu, PhD

Blood (2008) 112 (11): 4121.

https://doi.org/10.1182/blood.V112.11.4121.4121

Published: 2008

Journal Articles

Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension.

P.K. Epling-Burnette, PhD, Xianhong Chen, Junmin Zhou, Fanqi Bai, MD, Sokol Lubomir, MD, Edna Ku, MD, Jeffrey S. Painter, BS, Zou JianXiang, MD, Todd D. Edwards, MD, Djeu Y. Julie, PhD, Moscinski C. Lynn, MD, Thomas P. Loughran, MD, Sheng Wei, MD

Blood (2007) 110 (11): 4704.

https://doi.org/10.1182/blood.V110.11.4704.4704

Published: 2007

Journal Articles

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

P.K. Epling-Burnette, PhD, Lubomir Sokol, MD, Lynn Moscinski, MD, Magda Elkabani, MD, Fanqi Bai, MD, Michelle Blaskovich, BS, JianXiang Zou, MD, Jeffrey S. Painter, BS, Said Sebti, PhD, Thomas P. Loughran, MD

Blood (2007) 110 (11): 3132.

https://doi.org/10.1182/blood.V110.11.3132.3132

Published: 2007

Journal Articles

Constitutive Activation of Ras and Mitogen-Activated Protein Kinase (MAPK/ERK) in LGL Leukemia Unrelated to Activating Mutations in N and KRas Genes.

Jeffrey S. Painter, BS, Angela Costellanos, Fanqi Bai, MD, Sheng Wei, MD, Thomas P. Loughran, MD, P.K. Epling-Burnette, PhD

Blood (2007) 110 (11): 3180.

https://doi.org/10.1182/blood.V110.11.3180.3180

Published: 2007

Journal Articles

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Fanqi Bai, MD, J.-X. Zou, MD, Sheng Wei, MD, Jeffrey S. Painter, BS, Michelle Blaskovich, Bs, Said Sebti, PhD, Thomas P. Loughran, MD, P.K. Epling-Burnette, PhD

Blood (2007) 110 (11): 1331.

https://doi.org/10.1182/blood.V110.11.1331.1331

Published: 2007

Journal Articles

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

P.K. Epling-Burnette, PhD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Rollison Dana, PhD, JianXiang Zou, MD, Edna Ku, MD, Bin Zhong, BS, Sheng Wei, MD, Julie Y. Djeu, PhD, Alan F. List, MD

Blood (2006) 108 (11): 2651.

https://doi.org/10.1182/blood.V108.11.2651.2651

Published: 2006

Journal Articles

Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS).

Edna Ku, MD, PhD, JianXiang Zou, MD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2006) 108 (11): 2659.

https://doi.org/10.1182/blood.V108.11.2659.2659

Published: 2006

Journal Articles

Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS).

JianXiang Zou, MD, Edna Ku, MD, PhD, Fanqi Bai, MD, Jeffrey S. Painter, BS, Alan F. List, MD, P.K. Epling-Burnette, PhD

Blood (2006) 108 (11): 851.

https://doi.org/10.1182/blood.V108.11.851.851

Published: 2006

NARROW

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Molecular Characterization of SRSF2 Mutation Identifies a Clinically Relevant Lncrna (MALAT1) in Chronic Myelomonocytic Leukemia (CMML)

Association of MDM2 G ene Polymorphisms SNP285 and 309 with Myelodysplastic Syndromes (MDS) Susceptibility and Outcome.

Microenvironment Induced Myelodysplastic Syndrome (MDS) in S100A9 Transgenic Mice Caused by Myeloid-Derived Suppressor Cells (MDSC)

Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes.

Functional T Cell Array Reveals Pre-Treatment Expanded Terminal Effector Memory Response Is Associated with Lenalidomide Failure in Non-Del(5q) Myelodysplastic Syndrome.

Pathogenetic Role of Impaired Telomere Repair in Myelodysplastic Syndrome.

Co-Existance of JAK V617F and PIG-A mutations in Primary Budd-Chiari Syndrome.

Myeloid-Derived Suppressor Cells (MDSC) Are Effectors of Bone Marrow Suppression in Lower Risk Myelodysplastic Syndromes (MDS).

Molecular and Functional Analysis of Large Granular Lymphocyte Expansions in Chronic Myelogenous Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Therapy.

Altered Naive and Memory T Cell Homeostasis and Immunosenescence Characterize Younger Patients with Immunosuppressive-Responsive Myelodysplastic Syndrome

Dysregulated Distribution of Naïve and Memory FoxP3 Positive Regulatory T-Cells Associated with Anemia in Myelodysplastic Syndrome (MDS)

Genetic Disparities in Killer Cell Immunoglobulin-Like Receptors (KIR) and MHC Class I in Bone Marrow Failure Syndromes

Aberrant NK Receptor Signaling Associated with Large Granular Lymphoycte Leukemia and Primary Pulmonary Hypertension.

First Clinical Report of Tipifarnib for the Treatment of T-Large Granular Lymphocyte (LGL) Leukemia.

Constitutive Activation of Ras and Mitogen-Activated Protein Kinase (MAPK/ERK) in LGL Leukemia Unrelated to Activating Mutations in N and KRas Genes.

Th2 Polarization Induced by the Farnesyltransferase Inhibitor Tipifarnib (Zarnestra®, R115777) through Suppression of T-bet.

Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid®) Via a Mechanism Divergent from Interleukin-2 (IL-2).

Lenalidomide (CC5013, Revlimid®) Promotes T Helper-1 Function Bias and Increases Responsiveness to Autologous Bone Marrow Antigens in Myelodysplastic Syndrome (MDS).

Lenalidomide (CC5013, Revlimid®) Alters a T Cell Homeostatic Check-Point in Patients with Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only